Impact of Type 2 Diabetes and Postmenopausal Hormone Therapy on Incidence of Cognitive Impairment in Older Women

OBJECTIVE In older women, higher levels of estrogen may exacerbate the increased risk for cognitive impairment conveyed by diabetes. We examined whether the effect of postmenopausal hormone therapy (HT) on cognitive impairment incidence differs depending on type 2 diabetes. RESEARCH DESIGN AND METHODS The Women’s Health Initiative (WHI) randomized clinical trials assigned women to HT (0.625 mg/day conjugated equine estrogens with or without [i.e., unopposed] 2.5 mg/day medroxyprogesterone acetate) or matching placebo for an average of 4.7–5.9 years. A total of 7,233 women, aged 65–80 years, were classified according to type 2 diabetes status and followed for probable dementia and cognitive impairment (mild cognitive impairment or dementia). RESULTS Through a maximum of 18 years of follow-up, women with diabetes had increased risk of probable dementia (hazard ratio [HR] 1.54 [95% CI 1.16–2.06]) and cognitive impairment (HR 1.83 [1.50–2.23]). The combination of diabetes and random assignment to HT increased their risk of dementia (HR 2.12 [1.47–3.06]) and cognitive impairment (HR 2.20 [1.70–2.87]) compared with women without these conditions, interaction P = 0.09 and P = 0.08. These interactions appeared to be limited to women assigned to unopposed conjugated equine estrogens. CONCLUSIONS These analyses provide additional support to a prior report that higher levels of estrogen may exacerbate risks that type 2 diabetes poses for cognitive function in older women. The role estrogen plays in suppressing non–glucose-based energy sources in the brain may explain this interaction.

[1]  Michael E. Miller,et al.  Cognitive function and fine motor speed in older women with diabetes mellitus: results from the women's health initiative study of cognitive aging. , 2011, Journal of women's health.

[2]  A. Bhansali,et al.  Diabetes mellitus and risk of dementia: A meta‐analysis of prospective observational studies , 2013, Journal of diabetes investigation.

[3]  Leon Bieber,et al.  Sas System For Mixed Models , 2016 .

[4]  D. Jeste,et al.  Diagnostic validity of the dementia questionnaire for Alzheimer disease. , 1998, Archives of neurology.

[5]  R. Brinton,et al.  Early Decline in Glucose Transport and Metabolism Precedes Shift to Ketogenic System in Female Aging and Alzheimer's Mouse Brain: Implication for Bioenergetic Intervention , 2013, PloS one.

[6]  R. Brinton,et al.  Impact of progestins on estrogen-induced neuroprotection: synergy by progesterone and 19-norprogesterone and antagonism by medroxyprogesterone acetate. , 2002, Endocrinology.

[7]  J. Marchini,et al.  Fast and accurate genotype imputation in genome-wide association studies through pre-phasing , 2012, Nature Genetics.

[8]  J. Manson,et al.  Postmenopausal hormone therapy, type 2 diabetes mellitus, and brain volumes , 2015, Neurology.

[9]  Jin-Tai Yu,et al.  Midlife vascular risk factors and the risk of Alzheimer's disease: a systematic review and meta-analysis. , 2014, Journal of Alzheimer's disease : JAD.

[10]  Wiro J Niessen,et al.  POSTMENOPAUSAL HORMONE THERAPY AND REGIONAL BRAIN VOLUMES: THE WHIMS-MRI STUDY , 2009, Neurology.

[11]  A. Brickman,et al.  Telephone-based identification of mild cognitive impairment and dementia in a multicultural cohort. , 2011, Archives of neurology.

[12]  B. Howard,et al.  Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women’s Health Initiative Hormone Trial , 2004, Diabetologia.

[13]  References , 1971 .

[14]  R. Brinton.  Estrogen-induced plasticity from cells to circuits: predictions for cognitive function. , 2009, Trends in pharmacological sciences.

[15]  M. Espeland,et al.  Ascertaining dementia‐related outcomes for deceased or proxy‐dependent participants: an overview of the Women's Health Initiative Memory Study supplemental case ascertainment protocol , 2012, International journal of geriatric psychiatry.

[16]  M. Combrinck,et al.  The Validity and Reliability of 6 Sets of Clinical Criteria to Classify Alzheimer’s Disease and Vascular Dementia in Cases Confirmed Post-Mortem: Added Value of a Decision Tree Approach , 2003, Dementia and Geriatric Cognitive Disorders.

[17]  E. Cadenas,et al.  Perimenopause as a neurological transition state , 2015, Nature Reviews Endocrinology.

[18]  T. Morgan,et al.  The perimenopausal aging transition in the female rat brain: decline in bioenergetic systems and synaptic plasticity , 2015, Neurobiology of Aging.

[19]  JoAnn E. Manson,et al.  Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. , 1998, Controlled clinical trials.

[20]  E. Cadenas,et al.  Decline in mitochondrial bioenergetics and shift to ketogenic profile in brain during reproductive senescence. , 2010, Biochimica et biophysica acta.

[21]  E. Cadenas,et al.  Medroxyprogesterone acetate antagonizes estrogen up-regulation of brain mitochondrial function. , 2011, Endocrinology.

[22]  R. Brinton,et al.  The healthy cell bias of estrogen action: mitochondrial bioenergetics and neurological implications , 2008, Trends in Neurosciences.

[23]  L. Thal,et al.  Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study , 2004, JAMA.

[24]  Oscar L. Lopez,et al.  Telephone Interview for Cognitive Status , 2009, Neuroepidemiology.

[25]  M A Espeland,et al.  The Women's Health Initiative Memory Study (WHIMS): a trial of the effect of estrogen therapy in preventing and slowing the progression of dementia. , 1998, Controlled clinical trials.

[26]  Jennifer G. Robinson,et al.  Influence of Type 2 Diabetes on Brain Volumes and Changes in Brain Volumes , 2012, Diabetes Care.

[27]  Lewis H Kuller,et al.  Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. , 2013, JAMA.

[28]  R. Hamilton,et al.  Mitochondrial bioenergetic deficit precedes Alzheimer's pathology in female mouse model of Alzheimer's disease , 2009, Proceedings of the National Academy of Sciences.

[29]  J. Dartigues,et al.  High plasma estradiol interacts with diabetes on risk of dementia in older postmenopausal women , 2014, Neurology.

[30]  Jennifer G. Robinson,et al.  Validity of diabetes self-reports in the Women's Health Initiative: comparison with medication inventories and fasting glucose measurements , 2008, Clinical trials.

[31]  C. Björkelund,et al.  Physical Activity, Weight Status, Diabetes and Dementia: A 34-Year Follow-Up of the Population Study of Women in Gothenburg , 2014, Neuroepidemiology.

[32]  J. Manson,et al.  Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. , 2003, JAMA.

[33]  Susan M Resnick,et al.  Validation of a Cognitive Assessment Battery Administered over the Telephone , 2012, Journal of the American Geriatrics Society.

[34]  JoAnn E Manson,et al.  Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study. , 2004, JAMA.

[35]  JoAnn E. Manson,et al.  Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study. , 2004 .

[36]  G. Heiss,et al.  The effect of conjugated equine oestrogen on diabetes incidence: the Women’s Health Initiative randomised trial , 2006, Diabetologia.

[37]  Robert B Wallace,et al.  Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. , 2003, JAMA.

[38]  A. Venn,et al.  Brain Atrophy in Type 2 Diabetes , 2013, Diabetes Care.

[39]  C. Lyketsos,et al.  Modifiable predictors of dementia in mild cognitive impairment: a systematic review and meta-analysis. , 2015, The American journal of psychiatry.

[40]  H. Chui,et al.  The Modified Mini-Mental State (3MS) examination. , 1987, The Journal of clinical psychiatry.

[41]  S. Resnick,et al.  Long‐Term Effects of Conjugated Equine Estrogen Therapies on Domain‐Specific Cognitive Function: Results from the Women's Health Initiative Study of Cognitive Aging Extension , 2010, Journal of the American Geriatrics Society.